Page 86 - Read Online

Page 8 of 8 Jafri et al. Hepatoma Res 2018;4:54 I http://dx.doi.org/10.20517/2394-5079.2018.36

16. Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World J
Gastroenterol 2009;15:5647-53.
17. Bosan A, Qureshi H, Bile KM, Ahmad I, Hafiz R. A review of hepatitis viral infections in Pakistan. J Pak Med Assoc 2010;60:1045-58.
18. Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HU. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national
survey appealing for effective prevention and control measures. East Mediterr Health J 2010;16 Suppl:S15-23.
19. Centers for Disease Control and Prevention (CDC). Establishment of a viral hepatitis surveillance system--Pakistan, 2009-2011. MMWR
Morb Mortal Wkly Rep 2011;60:1385-90.
20. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection.
Journal of hepatology. J Hepatol 2014;61:S45-57.
21. Lim AG, Qureshi H, Mahmood H, Hamid S, Davies CF, Trickey A, Glass N, Saeed Q, Fraser H, Walker JG, Mukandavire C, Hickman M,
Martin NK, May MT, Averhoff F, Vickerman P. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and
prevention for achieving elimination. International journal of epidemiology. Int J Epidemiol;47:550-60.
22. Estes C, Abdel-Kareem M, Abdel-Razek W, Abdel-Sameea E, Abuzeid M, Gomaa A, Osman W, Razavi H, Zaghla H, Waked I. Economic
burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther 2015;42:696-706.
23. EMCDDA. European drug report 2017: trends and developments. Available from: http://www.emcdda.europa.eu/system/files/
publications/4541/TDAT17001ENN.pdf. [Last accessed on 17 Aug 2018]
24. Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P,
Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC,
Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group. Sofosbuvir and
velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4,
multicentre trial. Lancet Gastroenterol Hepatol 2018;3:153-61.
25. Lazarus JV, Safreed-Harmon K, Stumo SR, Jauffret-Roustide M, Maticic M, Reic T, Schatz E, Tallada J, Harris M; Hep-CORE Study
Group. Restrictions on access to direct-acting antivirals for people who inject drugs: the European Hep-CORE study and the role of patient
groups in monitoring national HCV responses. Int J Drug Policy 2017;47:47-50.
26. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam
I. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355:887-91.
27. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman
S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB,
Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML,
Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M,
Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho
RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji
A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W,
Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis
N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C. The present and future disease burden of hepatitis C virus (HCV)
infection with today’s treatment paradigm. J Viral Hepat 2014;21 Suppl 1:34-59.
28. El-Akel W, El-Sayed MH, El Kassas M, El-Serafy M, Khairy M, Elsaeed K, Kabil K, Hassany M, Shawky A, Yosry A, Shaker MK,
ElShazly Y, Waked I, Esmat G, Doss W. National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J Viral
Hepat 2017;24:262-7.
29. Ismail FW, Abid S, Mawani M, Jafri W, Hamid SS. Training in emerging advances in chronic hepatitis C infection in Pakistan: the Teach-
Pak project. Adv Med Educ Pract 2018;9:99-106.